natgillin/translations-raw huggingface dataset:
In this age group, 235 paediatric subjects received one dose and 340 subjects received two doses. 
V tej starostni skupini je 235 pediatričnih oseb prejelo en odmerek, 340 oseb pa je prejelo dva odmerka.
The available safety data in the paediatric population are presented below. 
Razpoložljivi podatki o varnosti za pediatrično populacijo so predstavljeni v nadaljevanju.
Currently available safety and immunogenicity data are described in sections 4.8 and 5.1 but no recommendation on posology can be made. 
Trenutno razpoložljivi podatki o varnosti in imunogenosti so opisani v poglavjih 4.8 in 5.1, vendar priporočil za odmerjanje ni mogoče dati.
The non-inferiority data observed are summarised in Table 2. 
Ugotovljeni podatki o neinferiornosti so povzeti v preglednici 2.
(≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100), not known (cannot be estimated from the available data). 
(≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The following side effects have been reported during clinical trials and during general use: 
O naslednjih neželenih učinkih so poročali med kliničnimi preskušanji in med splošno uporabo:
You can also report side effects directly via the national reporting system listed in Appendix V.* By reporting side effects, you can help provide more information on the safety of this medicine. 
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V.* S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
Read all of this leaflet carefully before you receive this medicine because it contains important information for you. 
Pred začetkom uporabe zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. 
Za boljšo sledljivost bioloških zdravil je treba jasno zabeležiti ime in številko serije apliciranega zdravila.
For instructions on the handling of the vaccine before administration, see section 6.6. 
Za navodila glede ravnanja s cepivom pred apliciranjem glejte poglavje 6.6.
Adults and children from 9 years of age: One dose of 0.5 ml 
Odrasli in otroci, stari 9 let ali več: en odmerek 0,5 ml
When a person is given the vaccine, the immune system (the body's natural defence system) will produce its own protection against the influenza virus. 
Ko je oseba cepljena, bo imunski sistem (naravni obrambni sistem telesa) začel proizvajati lastno zaščito proti virusu gripe.
It is important that procedures are in place to avoid injury from faints. 
Pomembno je, da poskrbite za ukrepe za preprečitev poškodb v primeru omedlevice.
• the active ingredients or any of the other ingredients of this medicine (listed in section 6) 
• učinkovino(-e) ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
Abbreviations: GMT = geometric mean titre; CI = confidence interval. 
Okrajšave: GMT = geometrična sredina titra; IZ = interval zaupanja.
None of the ingredients in the vaccine can cause flu. 
Nobena od sestavin cepiva ne more povzročiti gripe.
A protective immune response may not be elicited in all vaccine recipients. 
Varovalni imunski odziv morda ne bo dosežen pri vseh prejemnikih cepiva.
No effects on breast fed newborn/infant are anticipated. 
Učinkov na dojene novorojence/otroke se ne pričakuje.
Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient to prevent influenza. 
Odziv protiteles pri bolnikih z endogeno ali iatrogeno imunosupresijo morda ne bo zadosten za preprečitev gripe.
Compared to adults 18 years of age and older, paediatric subjects generally reported higher rates of local and systemic adverse reactions. 
V primerjavi z odraslimi osebami, starimi 18 let ali več, so pediatrični udeleženci na splošno poročali o višjih stopnjah lokalnih in sistemskih neželenih učinkov.
• You should tell your doctor if your immune system is impaired, or if you are undergoing treatment which affects the immune system, e.g. with medicine against cancer (chemotherapy) or corticosteroid medicines (see section “Other medicines and Flucelvax Tetra”). 
• morate vi povedati zdravniku, če je vaš imunski sistem okvarjen ali prejemate zdravljenje, ki vpliva na imunski sistem, npr. zdravila proti raku (kemoterapija) ali kortikosteroidna zdravila (glejte poglavje 2, "Druga zdravila in cepivo Flucelvax Tetra");
• You should tell your doctor if you have an acute illness associated with fever. 
• morate vi povedati zdravniku, če imate akutno bolezen, ki je povezana z zvišano telesno temperaturo.
For any information about this medicine, please contact the local representative of the Marketing Authorization Holder: 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
Pharmacotherapeutic group: Influenza vaccine, ATC code: J07BB02 
Farmakoterapevtska skupina: Cepiva proti gripi, oznaka ATC: J07BB02
Influenza cases were identified by active and passive surveillance of influenza-like illness (ILI). 
Primere gripe so ugotavljali z aktivnim in pasivnim spremljanjem gripi podobne bolezni (ILIinfluenza-like illness).
A single syringe contains 0.5 ml of suspension for injection. 
Ena brizga vsebuje 0,5 ml suspenzije za injiciranje.
Bold = Non-inferiority criterion met. 
Krepki tisk = Izpolnjeno merilo neinferiornosti.
Children less than 9 years of age reported similar rates of adverse reactions compared to older children. 
Otroci, mlajši od 9 let, so poročali o podobnih stopnjah neželenih učinkov kot starejši otroci.
Seqirus Vaccines Limited Gaskill Road, Speke L24 9GR Liverpool United Kingdom 
Seqirus Vaccines Limited Gaskill Road, Speke L24 9GR Liverpool Velika Britanija
In some human studies, antibody titres of 1:40 or greater have been associated with protection from influenza illness in up to 50% of subjects. 
V nekaterih študijah pri ljudeh so bili titri protiteles 1 : 40 ali višji povezani z zaščito pred gripo pri do 50 % udeležencev.
However, inactivated influenza vaccines can be used in all stages of pregnancy. 
Vendar pa se inaktivirana cepiva proti gripi lahko uporablja v vseh fazah nosečnosti.
ILI was defined according to Centers for Disease Control and Prevention (CDC) case definition, i.e., a fever (oral temperature ≥100.0°F / 38°C) and cough or sore throat. 
ILI je bila opredeljena skladno z opredelitvijo primera Centrov za nadzor in preprečevanje bolezni (CDC - Centers for Disease Control and Prevention), t. j. zvišana telesna temperatura (oralna temperatura ≥ 100,0 °F/38 °C) in kašelj ali boleče grlo.
This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. 
Spremlja jo lahko več nevroloških znakov, kot so prehodna motnja vida, parestezija in tonično-klonični gibi okončin med okrevanjem.
Annual revaccination with current influenza vaccines is recommended because immunity declines during the year after vaccination and circulating strains of influenza virus may change from year to year. 
Priporoča se vsakoletno cepljenje s trenutnim cepivi proti gripi, ker v letu po cepljenju imunost upade, sevi virusa gripe v obtoku pa se lahko vsako leto spreminjajo.
Comparison of immunogenicity of TIVc in the paediatric and adult population 
Primerjava imunogenosti TIVc pri pediatrični in odrasli populaciji
The immune response to each of the vaccine antigens was assessed 21 days after vaccination. 
Imunski odziv na vsakega od antigenov cepiva so ocenili 21 dni po cepljenju.
Similar rates of local and system adverse reactions were reported in the overall paediatric population 4 to < 18 years of age. 
O podobnih stopnjah lokalnih in sistemskih neželenih učinkov so poročali v splošni pediatrični populaciji, starosti od 4 leta do <18 let.
These antibodies neutralise influenza viruses. 
Ta protitelesa onemogočijo viruse gripe.
Tell your doctor immediately if you experience any of the following side effects - you may need medical attention: 
Takoj povejte zdravniku, če opazite katerega koli od naslednjih neželenih učinkov; morda boste potrebovali medicinsko pomoč:
B * Simultaneous one-sided 97.5% confidence intervals for the vaccine efficacy of each influenza vaccine relative to placebo based on the Sidak-corrected score confidence intervals for the two relative risks. 
* Sočasni enostranski 97,5-% intervali zaupanja za učinkovitost cepiva za vsako cepivo proti gripi v primerjavi s placebom, na osnovi intervalov zaupanja vrednosti s Sidakovim popravkom za relativni tveganji.
• difficulty in breathing, dizziness, a weak and rapid pulse and skin rash which are symptoms of an anaphylactic reaction (a very severe allergic reaction) 
• težave pri dihanju, omotičnost, šibek in hiter srčni utrip ter kožni izpuščaj, ki so simptomi anafilaktične reakcije (zelo hude alergijske reakcije).
Influenza vaccinations can be used at any stage of pregnancy. 
Cepiva proti gripi se lahko uporabljajo v vseh fazah nosečnosti.
% Lower Limit of OneSided 97.5% CI 
% Spodnja meja enostranskega 97,5-% IZ
It should be noted that both V58P12 and V58P13 were performed in the 2007-2008 northern hemisphere influenza season. 
da sta bili študiji V58P12 in V58P13 izvedeni na severni polobli med sezono gripe 2007-2008.
Ask you pharmacist how to throw away medicines you no longer use. 
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
• You should tell your doctor if you have a bleeding problem or bruise easily. 
• morate vi povedati zdravniku, če imate težave s krvavenjem ali hitro dobite modrice;
Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. 
Poleg tega protitelo proti eni antigenski različici virusa gripe lahko ne obvaruje pred novo antigensko različico istega tipa ali podtipa.
Paediatric population (9 to less than 18 years of age) 
Pediatrična populacija (od 9 let do manj kot 18 let)
Your doctor may decide to delay your vaccination until your fever is gone. 
Zdravnik se bo morda odločil, da vaše cepljenje preloži, dokler zvišana telesna temperatura ne mine;
Tell your doctor if you are pregnant, think you may be pregnant or are planning to have a baby. 
Če ste noseči, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom.
Hardening or swelling at the site of the injection, headache, muscle pain, and fatigue were common in the elderly. 
Neželeni učinki otrditev ali otekanje na mestu injiciranja, glavobol, bolečine v mišicah in utrujenost so bili pri starejših pogosti.
a The comparator vaccine for noninferiority comparisons for A/H1N1, A/H3N2 and B1 is TIV1c, for B2 it is 
a Primerjalno cepivo za primerjave neinferiornosti za A/H1N1, A/H3N2 in B1 je TIV1c, za B2 pa TIV2c.
• beta-propiolactone, cetyltrimethylammonium bromide, or polysorbate 80, which are trace residues from the manufacturing process. 
• beta-propiolakton, cetiltrimetilamonijev bromid ali polisorbat 80, ki so ostanki v sledeh, ki nastanejo med postopkom izdelave.
• Fainting can occur following, or even before, any needle injection, therefore tell the doctor or nurse if you fainted with a previous injection. 
• pri vsakem injiciranju z injekcijsko iglo ali celo pred njim lahko pride do omedlevice, zato morate vi povedati zdravniku, če ste že kdaj omedleli pri injiciranju.
In this study, 1159 paediatric subjects received Flucelvax Tetra (584 subjects aged > 9 to < 18 years; 575 subjects aged > 4 to < 9 years). 
V tej študiji je 1.159 pediatričnih oseb prejelo cepivo Flucelvax Tetra (584 oseb, starih > 9 let do < 18 let, in 575 oseb, starih > 4 leta do < 9 let).
Male fertility has not been assessed in animals. 
Plodnost samcev pri živalih ni bila ocenjena.
Flucelvax Tetra is manufactured using Madin Darby Canine Kidney (MDCK) cells. 
Cepivo Flucelvax Tetra je izdelano z uporabo celic pasjih ledvic Madin Darby Canine Kidney (MDCK).
Tell your doctor immediately or go to the casualty department at your nearest hospital if you experience the following side effect - you may need urgent medical attention or hospitalisation: 
Takoj povejte zdravniku ali pojdite v ambulanto za nujne primere v najbližjo bolnišnico, če opazite naslednje neželene učinke; morda boste potrebovali nujno medicinsko pomoč ali se boste morali zdraviti v bolnišnici:
Flucelvax Tetra should be used in accordance with official recommendations. 
Cepivo Flucelvax Tetra je treba uporabljati v skladu z uradnimi priporočili.
After an episode of ILI, nose and throat swab samples were collected for analysis. 
Po epizodi ILI so zbrali brise nosu in grla za analizo.
Flucelvax Tetra is a vaccine against flu (influenza). 
Flucelvax Tetra je cepivo proti gripi (influenci).
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to possible trace residues such as beta-propiolactone, cetyltrimethylammonium bromide, and polysorbate 80. 
Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1, ali na morebitne ostanke snovi v sledeh, kot so beta-propiolakton, cetiltrimetilamonijev bromid in polisorbat 80.
Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine. 
Vedno morata biti na voljo ustrezno zdravljenje in zdravstveni nadzor za primer redke anafilaktične reakcije po uporabi cepiva.
Children 9 to less than 18 years of age received a single dose of Flucelvax Tetra. 
Otroci, stari od 9 let do manj kot 18 let, so prejeli en odmerek cepiva Flucelvax Tetra.
As with all vaccines, Flucelvax Tetra may not fully protect all persons who are vaccinated. 
Kot pri vseh cepivih, tudi pri cepivu Flucelvax Tetra velja, da morda ne bo zagotovilo popolne zaščite vsem ljudem, ki so cepljeni.
Flucelvax Tetra has no or negligible influence on the ability to drive and use machines. 
Cepivo Flucelvax Tetra nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Fever (≥ 38°C) 
(≥38 °C)
Flucelvax Tetra provides active immunisation against four influenza virus strains (two A subtypes and two B types) contained in the vaccine. 
Cepivo Flucelvax Tetra daje aktivno imunizacijo proti štirim sevom virusa gripe (dva podtipa A in dva podtipa B), ki jih vsebuje.
The preferred site for injection is the deltoid muscle of the upper arm. 
Preferenčno mesto za injiciranje je deltoidna mišica nadlahti.
After shaking, the normal appearance of the vaccine is a clear to slightly opalescent suspension. 
Normalen videz cepiva po pretresanju je bistra do rahlo opalescentna suspenzija.
V58P13 (Subjects 18 to < 50 years) 
V58P13 (osebe, stare od 18 let do < 50 let)
A total of 11,404 subjects were enrolled to receive TIVc (N = 3828), Agrippal (N = 3676) or placebo (N = 3900) in a 1:1:1 ratio. 
Skupno je bilo vključenih 11.404 oseb, ki so prejele cepivo TIVc (N = 3.828), cepivo Agrippal (N = 3.676) ali placebo (N = 3.900), in sicer v razmerju 1 : 1 : 1.
Table 5: GMTs and seroconversion rates in adult and paediatric subjects vaccinated with TIVc (V58P12 and V58P13) 
Preglednica 5: GMT in stopnje serokonverzije pri odraslih in pediatričnih osebah, cepljenih s cepivom TIVc (V58P12 in V58P13)
Immune responses following vaccination with TIVc in the paediatric population (9 to < 18 years) were similar to those observed in the adult population in study V58P13 (see Table 5) in whom efficacy was demonstrated (results on vaccine efficacy are presented in Table 3). 
Imunski odzivi po cepljenju s cepivom TIVc pri pediatrični populaciji (od 9 let do < 18 let) so bili podobni tistim, ki so jih opazili pri odrasli populaciji v študiji V58P13 (glejte preglednico 5), pri kateri so dokazali učinkovitost (rezultati učinkovitosti cepiva so prikazani v preglednici 3).
There was no evidence that the addition of the second influenza B strain resulted in immune interference to other strains included in the vaccine. 
Ni bilo dokazov, da bi dodatek drugega seva virusa gripe B povzročil imunsko interferenco z drugimi sevi, vključenimi v cepivo.
• Your doctor or nurse will make sure that appropriate medical treatment and supervision is readily available in case of a rare anaphylactic reaction (a very severe allergic reaction with symptoms such as difficulty in breathing, dizziness, a weak and rapid pulse and skin rash) following the administration. 
PREDEN prejmete cepivo: • bosta zdravnik ali medicinska sestra zagotovila, da bosta na voljo ustrezno zdravljenje in zdravstveni nadzor za primer redke anafilaktične reakcije (zelo hude alergijske reakcije s simptomi, kot so težave pri dihanju, omotičnost, šibek in hiter srčni utrip ter kožni izpuščaj) po uporabi.
• Generalised skin reactions including itching, bumps on the skin or non-specific rash 
• splošne kožne reakcije, vključno s srbenjem, bulami na koži ali neznačilnim izpuščajem.
Flucelvax Tetra injection Influenza vaccine 2019/2020 season 
Flucelvax Tetra injekcija cepivo proti gripi sezona 2019/2020
Fever was common in adolescents and children. 
Zvišana telesna temperatura je bila pri mladostnikih in otrocih pogosta.
The vaccine targets four strains of influenza virus following the recommendations by the World Health Organisation for the 2019/2020 season. 
Cepivo je usmerjeno na štiri seve virusa gripe, skladno s priporočili Svetovne zdravstvene organizacije za sezono 2019/2020.
TIVc efficacy was defined as the prevention of culture-confirmed symptomatic influenza illness caused by viruses antigenically matched to those in the vaccine compared to placebo. 
Učinkovitost cepiva TIVc je bila opredeljena kot preprečevanje s kulturo celic potrjene simptomatične gripe, ki jo povzročajo virusi, ki se antigensko ujemajo s tistimi v cepivu, v primerjavi s placebom.
In the paediatric population 4 to less than 6 years of age, the following additional solicited adverse reactions were reported: sleepiness (21%), irritability (19%) and change in eating habits (14%). 
V okviru sistematičnega poročanja so pri pediatrični populaciji starosti od 4 leta do manj kot 6 let poročali o naslednjih dodatnih neželenih učinkih: zaspanost (21 %), razdražljivost (19 %) in sprememba prehranjevalnih navad (14 %).
Overall, the immunogenicity results were in line with those obtained in subjects older than 9 years of age and showed a similar immune response in subjects receiving Flucelvax Tetra as compared to those receiving a comparator TIVc. 
Na splošno so se rezultati imunogenosti ujemali s tistimi, pridobljenimi pri osebah, starejših od 9 let, in so pokazali podoben imunski odziv pri osebah, ki so prejele cepivo Flucelvax Tetra, in osebah, ki so prejele primerjalno cepivo TIVc.
In children who received a second dose of Flucelvax Tetra or cell-based trivalent influenza vaccine, the incidence of adverse reactions following the second dose of vaccine was similar to that observed with the first dose in this clinical trial. 
Pri otrocih, ki so prejeli drugi odmerek cepiva Flucelvax Tetra ali trivalentnega cepiva proti gripi na celični osnovi, je bila incidenca neželenih učinkov po drugem odmerku cepiva podobna tisti, ki so jo opazili po prvem odmerku v tem kliničnem preskušanju.
0.5 ml suspension in pre-filled syringes (type I glass), with a plunger stopper (bromobutyl rubber), with or without needle. 
0,5 ml suspenzije v napolnjenih injekcijskih brizgah (steklo tipa I) z batnim zamaškom iz bromobutilne gume, z iglo ali brez nje.
Seroconversion Rateb a For H1N1, H3N2 and B1 influenza strains TIV1c data are presented, whereas for B2 influenza strain TIV2c data are presented. 
Stopnja serokonverzijeb a Za seve gripe H1N1, H3N2 in B1 so prikazani podatki za TIV1c, za sev gripe B2 pa so prikazani podatki za TIV2c.
Bold- CHMP immunogenicity criteria met. 
Krepki tisk - Izpolnjena merila imunogenosti CHMP.
As with all injectable vaccines, Flucelvax Tetra must be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration. 
Kot pri vseh cepivih, ki se injicirajo, je tudi pri cepivu Flucelvax Tetra potrebna previdnost, ko se ga daje osebam s trombocitopenijo ali motnjo hemostaze, saj lahko pride do krvavitve po intramuskularni aplikaciji.
The percentage of subjects with seroconversion or significant increase in HI antibody titre is >40%, the percentage of subjects achieving an HI titre ≥1:40 is >70%. 
Odstotek oseb s serokonverzijo ali značilnim zvišanjem titra protiteles HI je > 40 %, odstotek oseb, ki so dosegle titer HI ≥ 1 : 40, je > 70 %.
What you need to know before you receive Flucelvax Tetra You should not receive Flucelvax Tetra: 
Kaj morate vedeti, preden boste prejeli cepivo Flucelvax Tetra Ne smete prejeti cepiva Flucelvax Tetra,
Flucelvax Tetra is available in packs containing 1 pre filled syringe with needle or 10 prefilled syringes with or without needles. 
Cepivo Flucelvax Tetra je na voljo v pakiranjih z 1 napolnjeno injekcijsko brizgo ali 10 napolnjenimi injekcijskimi brizgami z iglami ali brez njih.
This vaccine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium free'. 
To cepivo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni "brez natrija".
V58P12 (Subjects 9 to < 18 years) 
V58P12 (osebe, stare od 9 let do < 18 let)
The incidence of some adverse reactions were considerably lower among subjects ≥ 65 years of age when compared to subjects 18 to < 65 years of age (see table below). 
Incidenca nekaterih neželenih učinkov je bila pri osebah, starih 65 let ali več, znatno manjša kot pri osebah, starih od 18 let do manj kot 65 let (glejte spodnjo preglednico).
The available immunogenicity data in the paediatric population 4 to less than 9 years of age were obtained in trial V130_03. 
Razpoložljivi podatki o imunogenosti za pediatrično populacijo starosti od 4 leta do manj kot 9 let so bili pridobljeni v preskušanju V130_03.
Do not use this vaccine after the expiry date which is stated on the label and carton after EXP. 
Tega cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
MedDRA System Organ class Very common 
Organski sistem po MedDRA Zelo pogosti
Flucelvax Tetra may contain traces of beta-propiolactone, cetyltrimethylammonium bromide, and polysorbate 80. 
Cepivo Flucelvax Tetra lahko vsebuje sledi beta-propiolaktona, cetiltrimetilamonijevega bromida in polisorbata 80.
The immunogenicity data in subjects 9 to less than 18 years of age are summarised in Table 4. 
Podatki o imunogenosti pri otrocih, starih od 9 let do manj kot 18 let, so povzeti v preglednici 4.
Prophylaxis of influenza in adults and children from 9 years of age. 
Preprečevanje gripe pri odraslih in otrocih, starih 9 let ali več.
Table 4: GMTs and seroconversion rates (with 95% CI) in subjects 9 to <18 years of age, 3 weeks after vaccination with Flucelvax Tetra or TIV1c/TIV2c - Per Protocol Set (V130_03) 
Preglednica 4: GMT in stopnje serokonverzije (95-% IZ) pri osebah, starih od 9 let do < 18 let, 3 tedne po cepljenju s cepivom Flucelvax Tetra ali TIV1c/TIV2c - nabor za analizo po protokolu (V130_03)
Children 4 to less than 9 years of age received one or two doses (separated by 4 weeks) of Flucelvax Tetra based on determination of the subject's prior influenza vaccination history. 
Otroci, stari od 4 leta do manj kot 9 let, so prejeli en ali dva odmerka cepiva Flucelvax Tetra (v presledku 4 tednov), na osnovi ugotovljene zgodovine cepljenja proti gripi pri posamezniku.
The vaccine should be visually inspected for particulate matter and discoloration prior to administration. 
Cepivo je treba pred dajanjem vizualno pregledati glede prisotnosti delcev in razbarvanja.
This vaccine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially ‘potassium free'. 
To cepivo vsebuje manj kot 1 mmol (39 mg) kalija na odmerek, kar v bistvu pomeni "brez kalija".